Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News


Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

share with twitter share with LinkedIn share with facebook
share via e-mail
10/09/2013 | 03:06pm CET

Development Progress Builds on Encouraging Clinical Data in Idiopathic Pulmonary Fibrosis (IPF)

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is advancing PRM-151, a recombinant form of an endogenous human protein that offers the potential to prevent and potentially reverse fibrosis. The Phase 2 clinical study of PRM-151 in patients with myelofibrosis, which is expected to complete in 2014, expands Promedior's clinical focus beyond IPF to myelofibrosis, another serious, life-limiting orphan disease with significant unmet medical need.

"Advancing the clinical development of PRM-151, our lead product candidate, into clinical studies in myelofibrosis patients is a significant milestone for Promedior," said Elizabeth G. Trehu, MD, FACP, Promedior's Chief Medical Officer. "We are optimistic that data from this study, combined with the encouraging data in IPF, will demonstrate that PRM-151's novel mechanism of action is applicable to a wide range of fibrotic diseases."

Promedior's clinical development program in myelofibrosis with PRM-151 builds upon a randomized, placebo-controlled clinical study in patients with IPF, in which PRM-151 was generally safe and well?tolerated and resulted in a mean improvement in Forced Vital Capacity (FVC) at 8 weeks after dosing for only two weeks, whereas patients receiving placebo had a decline in FVC. In addition, PRM-151 has demonstrated broad anti-fibrotic activity in multiple industry standard preclinical models of fibrotic disease, including pulmonary fibrosis, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration.

"Despite the success of JAK inhibitors, there is still a critical need for new therapeutic approaches for patients with myelofibrosis. With its unique mechanism of action that offers the potential to prevent and reverse fibrosis, Promedior's PRM-151 has the potential to become a first-in-class disease-modifying treatment for this debilitating disease," said Srdan Verstovsek, MD, PhD, Professor and Section Chief for Myeloproliferative Neoplasms, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and principal investigator for the study.

This clinical trial is a multi-center, two stage, adaptive design Phase 2 study to determine the efficacy and safety of PRM-151 as a single agent or added to a stable dose of ruxolitinib in patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF). The primary endpoint is response rate according to the International Working Group- Myeloproliferative Neoplasms Research and Treatment criteria, a comprehensive assessment tool designed by an international group of experts to objectively measure the effectiveness of treatments for MF¹. Approximately 24 patients are expected to enroll in the first stage of the study, with up to 80 additional patients in the second stage. For additional details about this clinical trial, please visit www.clinicaltrials.gov.

About Myelofibrosis

Myelofibrosis (MF), a type of myeloproliferative neoplasm, is a serious, life-limiting cancer that is characterized by fibrosis of the bone marrow. Replacement of the bone marrow by scar tissue prevents the normal production of blood cells, leading to anemia, fatigue, and increased risk of bleeding and infection. Production of blood cells shifts to the spleen and liver (extramedullary hematopoiesis), which become enlarged, causing severe discomfort, inability to eat, and weakness. Symptomatic myelofibrosis affects approximately 18,000 people per year in the US, with a median age of 61-66.². The only potentially curative treatment is allogeneic bone marrow transplant, which results in reversal of fibrosis and all symptoms, but is a realistic option for only a small number of patients. Other currently available therapies address the symptoms, but have minimal if any impact on the underlying fibrosis.

About PRM-151

PRM-151, Promedior's lead product candidate, is a recombinant form of an endogenous human protein, Pentraxin-2 (PTX-2), that is specifically active at the site of tissue damage. PRM-151 is an agonist that acts as a macrophage differentiation factor to prevent and potentially reverse fibrosis. PRM-151 has shown broad anti-fibrotic activity in multiple preclinical models of fibrotic disease, including pulmonary fibrosis, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration.

Phase 1a and 1b clinical studies in healthy subjects and IPF patients have demonstrated that PRM-151 was safe and well tolerated. Additionally, a Phase 1b study in patients with IPF showed encouraging results in exploratory efficacy endpoints, which were presented in an oral session at the 2013 Annual Meeting of the American Thoracic Society³.

About Promedior

Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon Pentraxin-2, an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, potentially preventing and reversing fibrosis.

Promedior has successfully advanced its lead therapeutic candidate in human clinical trials, and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis. Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team. For additional information about Promedior, please visit www.promedior.com.

1. Tefferi, A., et al, "Revised Response Criteria for Myelofibrosis: International Working Group- Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report," Blood 122(8): 1395-8; 2013.
2. Mehta, J., Wang, H., Iqbal, S. U., Mesa, R., "Epidemiology of myeloproliferative neoplasms in the United States", Leukemia & Lymphoma, Early Online: 1-6, 2013.

Van Den Blink, B. et al., "A Phase I Study Of PRM-151 In Patients With Idiopathic Pulmonary Fibrosis", American Thoracic Society 2013 Annual Meeting, May 2013. Read More: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5707


The Yates Network
Kathryn Morris, 845-635-9828

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news
Date Title
01:31p Versartis to Host Conference Call to Review Data from ENDO 2017 on Long-Acting Somavaratan for Growth Hormone Deficiency
01:31p CARNIVAL : Princess Cruises to Add Guest Experience Platform to Two More Cruise Ships
01:31p CVS HEALTH : University of Pittsburgh School of Pharmacy and Pittsburgh Public Schools Announce Joint Effort to Prevent Youth Drug Abuse
01:31p VelocityEHS Highlights New Strategies at 2017 Applied Ergonomics Conference
01:31p AMPIO PHARMACEUTICALS : Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of n(TM)
01:31p Quadrant 4 System Corporation Announces Strategic Restructure of Core IT Services Business and Key Personnel Updates
01:31p WELLCARE HEALTH PLANS : Harmony Health Plan Enters into Contract with Christie Clinic
01:31p ALLISON TRANSMISSION : TC10® to be available in Kenworth and Peterbilt models this year
01:31p Galectin Therapeutics Issues Statement Regarding GALTW and GALTU
01:31p Global Self Storage to Present at The MicroCap Conference in New York City on April 4, 2017
Latest news
Hot News 
7.49%NEXT : Investors find some comfort in Next's chilly outlook
-3.97%BASIC FIT : core earnings rise on record number of new gym openings
2.26%GVC : to pay second special dividend for 2016 on favourable trading, refinancing
-5.67%TED BAKER : Retailer Ted Baker's profit rises on strong UK, Europe sales
-3.24%IG : quarterly revenue falls 3.8 percent on UK, Ireland weakness
Most Read News
04:02a Verizon, AT&T suspend ads from Google over offensive videos
06:51a NEXT : Investors find some comfort in Next's chilly outlook
03/22DJAT&T Pulling Ads From Google Over 'Hate' Videos -- 3rd Update
03/22DJSEARS : Stock Stumbles After Going-Concern Warning -- 3rd Update
05:10a UBS : set to charge wealthy for keeping euro savings
Most recommended articles
03/21 UK to investigate any UK banking involvement in 'Laundromat' case
08:28aDJMARKET SNAPSHOT : U.S. Stocks Set To Edge Up, As Health-care Vote, Yellen Take Center Stage
08:26a Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency
08:24a ANGLO AMERICAN : Diamond group De Beers buys out retail partner LVMH
08:23aDJDAIMLER : Faces Diesel-Engine Fraud Investigation in Germany--Update